Comparable stake leader
Krish S. Krishnan
SEC ownership of Krystal Biotech, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001711279.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- KRYS on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Krish S. Krishnan
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Krish S. Krishnan
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001711279
- Issuer location
- Pittsburgh, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Krystal Biotech, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Krish S. Krishnan
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 12%
13D/G row: Krish S. Krishnan
Showing 1-8 of 50 holder rows.
Quick read
Krish S. Krishnan leads the comparable SEC ownership view at 12%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Krish S. Krishnan's linked filing trail.
Comparable ownership
Top 5
Krish S. Krishnan
12%
VANGUARD PORTFOLIO MANAGEMENT LLC
5%
STATE STREET CORP
4.4%
Dino A. Rossi
0.27%
Daniel Janney
0.25%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Krish S. Krishnan |
13D/G
3/4/5
President and CEO, Director, 10%+ Owner
|
12%
|
$906,060,757
3,388,283 shares
|
$0 | 31 Mar 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
Vanguard Portfolio Management
|
5%
|
$382,084,101
1,479,111 shares
|
$0 | 31 Mar 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
4.4%
from 13D/G
|
$502,201,761
1,351,158 shares
|
— | 30 Jun 2026 |
| Dino A. Rossi |
3/4/5
Director
|
0.27%
|
$20,624,911
78,691 shares
|
-$4,953,694 | 19 Feb 2026 |
| Daniel Janney |
3/4/5
Director
|
0.25%
|
$20,241,071
73,293 shares
|
-$19,402,207 | 27 Feb 2026 |
| Laurent Louis Jean Goux |
3/4/5
EVP, Head of International
|
0%
|
$250,565
919 shares
|
— | 01 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
14%
|
$1,554,113,017
4,181,432 shares
|
— | 30 Jun 2026 |
| Soleus Capital Management, L.P. |
13F
Company
|
3.2%
|
$349,092,534
939,254 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$79,079,503.
Buys
$0
Insiders: 0
Sells
$79,079,503
Insiders: 6
Net
-$79,079,503
Shares: -305,806
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 305,806
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 51,642 | $0 | $15,946,982 | -$15,946,982 |
| 3-6 | 0 | 141,664 | $0 | $37,716,036 | -$37,716,036 |
| 6-9 | 0 | 112,500 | $0 | $25,416,485 | -$25,416,485 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Krystal Biotech, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Krish S. Krishnan
Net 12M change
-$79,079,502
Latest report
25 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Krish S. Krishnan | President and CEO, Director, 10%+ Owner | $522,185,363 | -$25,289,595 | -4.6% | Mixed | 04 Jun 2026 |
| Suma M. Krishnan | President, R&D, Director, 10%+ Owner | $496,996,320 | -$25,290,428 | -4.8% | Mixed | 04 Jun 2026 |
| Dino A. Rossi | Director | $20,624,911 | -$4,953,694 | -19% | Filing P/S | 19 Feb 2026 |
| Daniel Janney | Director | $20,241,071 | -$19,402,207 | -49% | Filing P/S | 27 Feb 2026 |
| Kathryn Romano | Chief Accounting Officer | $7,696,124 | -$3,602,405 | -32% | Mixed | 27 Feb 2026 |
| Laurent Louis Jean Goux | EVP, Head of International | $250,565 | Mixed | 01 Mar 2026 | ||
| Andrew C. Orth | Chief Commercial Officer | $13,000 | Mixed | 09 Jun 2023 | ||
| John C. Thomas | EVP, General Counsel | $0 | -$541,173 | -100% | Mixed | 25 Jun 2026 |
| Jing L. Marantz | Chief Business Officer | Mixed | 31 Jan 2022 | |||
| Christopher Mason | Director | Mixed | 30 Jun 2025 | |||
| Everett Rand Sutherland | Director | Mixed | 30 Jun 2025 | |||
| Catherine Mazzacco | Director | Mixed | 30 Jun 2025 | |||
| Julian S. Gangolli | Director | Mixed | 30 Jun 2025 |
Recent insider transactions for Krystal Biotech, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| John C. Thomas | KRYS | Common Stock | Sale | -100% | $347,270 | $347.27 | -1,000 | 0 | 25 Jun 2026 | Direct |
| John C. Thomas | KRYS | Common Stock | Options Exercise | 1,000 | 1,000 | 25 Jun 2026 | Direct | |||
| John C. Thomas | KRYS | Stock Option (Right to Buy) | Options Exercise | -13.3% | -1,000 | 6,500 | 25 Jun 2026 | Direct | ||
| Suma M. Krishnan | KRYS | Common Stock | Sale | -1.78% | $7,702,825 | $308.11 | -25,000 | 1,378,155 | 04 Jun 2026 | Direct |
| Krish S. Krishnan | KRYS | Common Stock | Sale | -1.69% | $7,702,984 | $308.12 | -25,000 | 1,450,253 | 04 Jun 2026 | Direct |
| John C. Thomas | KRYS | Common Stock | Sale | -100% | $193,903 | $302.03 | -642 | 0 | 26 May 2026 | Direct |
| Suma M. Krishnan | KRYS | Common Stock | Sale | -1.75% | $6,580,270 | $263.21 | -25,000 | 1,403,155 | 04 Mar 2026 | Direct |
| Krish S. Krishnan | KRYS | Common Stock | Sale | -1.67% | $6,579,164 | $263.17 | -25,000 | 1,475,253 | 04 Mar 2026 | Direct |
| Kathryn Romano | KRYS | Common Stock | Sale | -3.24% | $200,700 | $267.60 | -750 | 22,366 | 02 Mar 2026 | Direct |
| Kathryn Romano | KRYS | Common Stock | Tax liability | -13.3% | -3,502 | 22,806 | 27 Feb 2026 | Direct | ||
| Kathryn Romano | KRYS | Common Stock | Options Exercise | 44.7% | 8,050 | 26,068 | 27 Feb 2026 | Direct | ||
| Kathryn Romano | KRYS | Restricted Stock Units | Award | 5,442 | 5,442 | 27 Feb 2026 | Direct | |||
| Kathryn Romano | KRYS | Stock Option (Right to Buy) | Award | 13,575 | 13,575 | 27 Feb 2026 | Direct | |||
| Kathryn Romano | KRYS | Restricted Stock Units | Options Exercise | -25% | -550 | 1,650 | 27 Feb 2026 | Direct | ||
| Kathryn Romano | KRYS | Performance Stock Units | Options Exercise | -100% | -7,500 | 0 | 27 Feb 2026 | Direct | ||
| Suma M. Krishnan | KRYS | Common Stock | Tax liability | -1.23% | -18,528 | 1,482,825 | 27 Feb 2026 | By Spouse | ||
| Suma M. Krishnan | KRYS | Common Stock | Options Exercise | 2.77% | 40,725 | 1,509,075 | 27 Feb 2026 | By Spouse | ||
| Suma M. Krishnan | KRYS | Common Stock | Tax liability | -0.84% | -12,056 | 1,425,975 | 27 Feb 2026 | Direct | ||
| Suma M. Krishnan | KRYS | Common Stock | Options Exercise | 1.88% | 26,500 | 1,436,211 | 27 Feb 2026 | Direct | ||
| Suma M. Krishnan | KRYS | Performance Stock Units | Award | 43,536 | 43,536 | 27 Feb 2026 | Direct | |||
| Suma M. Krishnan | KRYS | Restricted Stock Units | Award | 7,256 | 7,256 | 27 Feb 2026 | Direct | |||
| Suma M. Krishnan | KRYS | Stock Option (Right to Buy) | Award | 18,100 | 18,100 | 27 Feb 2026 | Direct | |||
| Suma M. Krishnan | KRYS | Restricted Stock Units | Options Exercise | -25% | -4,000 | 12,000 | 27 Feb 2026 | Direct | ||
| Suma M. Krishnan | KRYS | Performance Stock Units | Options Exercise | -100% | -22,500 | 0 | 27 Feb 2026 | Direct | ||
| Krish S. Krishnan | KRYS | Common Stock | Tax liability | -0.84% | -12,056 | 1,425,975 | 27 Feb 2026 | By Spouse | ||
| Krish S. Krishnan | KRYS | Common Stock | Options Exercise | 1.88% | 26,500 | 1,436,211 | 27 Feb 2026 | By Spouse | ||
| Krish S. Krishnan | KRYS | Common Stock | Tax liability | -1.23% | -18,528 | 1,482,825 | 27 Feb 2026 | Direct | ||
| Krish S. Krishnan | KRYS | Common Stock | Options Exercise | 2.77% | 40,725 | 1,509,075 | 27 Feb 2026 | Direct | ||
| Krish S. Krishnan | KRYS | Restricted Stock Units | Award | 18,140 | 18,140 | 27 Feb 2026 | Direct | |||
| Krish S. Krishnan | KRYS | Stock Option (Right to Buy) | Award | 45,249 | 45,249 | 27 Feb 2026 | Direct | |||
| Krish S. Krishnan | KRYS | Performance Stock Units | Options Exercise | -100% | -26,250 | 0 | 27 Feb 2026 | Direct | ||
| Krish S. Krishnan | KRYS | Restricted Stock Units | Options Exercise | -45.7% | -14,475 | 17,175 | 27 Feb 2026 | Direct | ||
| Daniel Janney | KRYS | Common Stock | Sale | -13.9% | $3,252,824 | $275.59 | -11,803 | 73,293 | 27 Feb 2026 | Directly beneficially owned by Alta Bioequities, L.P. |
| Daniel Janney | KRYS | Common Stock | Sale | -8.34% | $2,133,679 | $275.63 | -7,741 | 85,096 | 26 Feb 2026 | Directly beneficially owned by Alta Bioequities, L.P. |
| Daniel Janney | KRYS | Common Stock | Sale | -0.75% | $192,500 | $275.00 | -700 | 92,837 | 25 Feb 2026 | Directly beneficially owned by Alta Bioequities, L.P. |
| Daniel Janney | KRYS | Common Stock | Sale | -12.9% | $3,709,850 | $268.34 | -13,825 | 93,537 | 24 Feb 2026 | Directly beneficially owned by Alta Bioequities, L.P. |
| Daniel Janney | KRYS | Common Stock | Sale | -100% | $10,113,354 | $266.88 | -37,895 | 0 | 24 Feb 2026 | Direct |
| Daniel Janney | KRYS | Common Stock | Options Exercise | 37,895 | 37,895 | 24 Feb 2026 | Direct | |||
| Daniel Janney | KRYS | Stock Option (Right to Buy) | Options Exercise | -100% | -37,895 | 0 | 24 Feb 2026 | Direct | ||
| Dino A. Rossi | KRYS | Common Stock | Sale | -19.4% | $4,953,694 | $261.41 | -18,950 | 78,691 | 19 Feb 2026 | Direct |
| Dino A. Rossi | KRYS | Common Stock | Options Exercise | 24.1% | 18,950 | 97,641 | 19 Feb 2026 | Direct | ||
| Dino A. Rossi | KRYS | Stock Option (Right to Buy) | Options Exercise | -100% | -18,950 | 0 | 19 Feb 2026 | Direct | ||
| Kathryn Romano | KRYS | Common Stock | Gift | -3.88% | -750 | 18,568 | 09 Feb 2026 | Direct | ||
| Kathryn Romano | KRYS | Common Stock | Sale | -39.3% | $3,401,705 | $272.14 | -12,500 | 19,318 | 09 Feb 2026 | Direct |
| Kathryn Romano | KRYS | Common Stock | Options Exercise | 64.7% | 12,500 | 31,818 | 09 Feb 2026 | Direct | ||
| Kathryn Romano | KRYS | Stock Option (Right to Buy) | Options Exercise | -50% | -12,500 | 12,500 | 09 Feb 2026 | Direct | ||
| Suma M. Krishnan | KRYS | Common Stock | Gift | -0.34% | -5,000 | 1,478,056 | 05 Dec 2025 | By Spouse | ||
| Krish S. Krishnan | KRYS | Common Stock | Gift | -0.34% | -5,000 | 1,478,056 | 05 Dec 2025 | Direct | ||
| Suma M. Krishnan | KRYS | Common Stock | Sale | -1.66% | $5,503,395 | $220.14 | -25,000 | 1,483,056 | 04 Dec 2025 | By Spouse |
| Suma M. Krishnan | KRYS | Common Stock | Sale | -1.74% | $5,503,938 | $220.16 | -25,000 | 1,413,711 | 04 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.